Testing Thero2-01S22 with standard HER2 therapy for metastatic breast cancer
Part of Cancer clinical trials.
This Phase 3 trial tests Thero2-01S22 in people with HER2-positive metastatic breast cancer who are starting their first anti-HER2 treatment. It aims to improve outcomes when combined with the usual HER2 medicines (trastuzumab and pertuzumab).
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a woman age 18 or older
- Have HER2-positive breast cancer that has spread (metastatic) and was confirmed by tissue testing
- Be starting your first treatment for metastatic disease, including trastuzumab plus pertuzumab
- Have a heart pumping measurement (LVEF) above 50% on an echo, heart MRI, or MUGA scan within 12 weeks
- Have overexpression of HER2 on the original tumor test (3+ or 2+ confirmed by special tests)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new medicine as the first treatment for HER2-positive breast cancer that has spread or cannot be removed. It's for women who have not had chemotherapy for advanced disease.
This trial tests a personalized treatment plan for HER2-positive breast cancer before surgery. The treatment is adjusted based on how your cancer responds, aiming to give you the best possible outcome.
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
This Phase 2 study tests a personalized immune-therapy vaccine made from your immune cells, given with weekly paclitaxel and HER2-targeted antibodies (trastuzumab and pertuzumab). It aims to improve treatment outcomes for people with HER2-positive breast cancer before standard local treatment (like surgery and radiation).
This trial tests a new drug called TQB2102 given before surgery for HER2-positive breast cancer. The goal is to see if it can shrink the tumor enough to allow a successful surgery.
This trial tests a drug for people with HER2-positive breast cancer that has spread to only a few places in the body (up to 5 spots). It aims to see if the treatment works well before starting stronger therapies.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.